<DOC>
	<DOCNO>NCT01205035</DOCNO>
	<brief_summary>Idiopathic Parafoveal Telangiectasia ( IPT ) [ also know Idiopathic Perifoveal Telangiectasia , Idiopathic Juxtafoveal Telangiectasia ( IJT , JFT ) Macular Telangiectasia ( MacTel ) ] disorder unknown etiology . IPT classify Group 2A Gass classification macular telangiectasias ( Reference 1,5 ) - bilateral , always symmetric disorder . It characterize early stage dilation loss parafoveal capillary accompany angiographic leakage , `` right angle '' venule , central parafoveal intraretinal cyst .</brief_summary>
	<brief_title>High-Dose Lucentis ( Ranibizumab 2.0mg ) Treatment Nonproliferative Idiopathic Parafoveal Telangiectasia</brief_title>
	<detailed_description>DESCRIPTION OF THE STUDY This open-label , Phase I/II study intravitreally administer ranibizumab subject nonproliferative Idiopathic Parafoveal Telangiectasia ( IPT ) . Consented , enrolled subject randomize two group : observation treatment . The observation group monitor monthly treatment group receive three open-label intravitreal injection 1.0 mg ranibizumab administer every 30 day 3 month need monthly , base define criterion . NOTE : The original protocol treatment group dose 2.0 mg/0.05mL . However , 2.0mg dose become unavailable begin January 31 , 2012 . Therefore , protocol amendment submit December 2011 change 2.0mg arm 1.0mg/ 0.10mL arm . Please note three patient already treat 2.0mg amendment submit , switch 1.0mg complete study 2.0 dose longer available January 2012 . Protocol : FVF4875s Final 6/P 29MAR2010 3.2 RATIONALE FOR STUDY DESIGN As IPT chronically progressive condition , purpose study see high-dose ranibizumab slow stop leakage growth exist , dilate , macular vessel case co-existing neovascularization exists define fluorescein angiography Ocular Coherence Tomography ( OCT ) . Other outcome include stabilization visual acuity compare observation group ( define best correct Early Treatment Diabetic Retinopathy Study ( ETDRS ) measurement ) , change ultrastructural feature , define OCT , 3.3 OUTCOME MEASURES 3.3.1 Primary Outcome Measures To compare change visual acuity baseline one year patient nonproliferative IPT either treat high-dose ( 1.0mg ) ranibizumab observe . 3.3.2 Secondary Outcome Measures . To compare change visual acuity baseline 6 month 9 month patient nonproliferative IPT either treat high- dose ( 1.0mg ) ranibizumab observe . ii . To assess OCT change standard Central Subfield Thickness ( CST ) baseline 6 month , 9 month 12 month . iii . To assess safety administer 1.0mg ranibizumab ( Lucentis ) patient nonproliferative IPT 6 month , 9 month 12 month . iv . To assess change angiographic leakage baseline 6 12 month .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Presence nonproliferative IPT confirm fluorescein angiography spectraldomain OCT Age great 18 Vision equal worse 20/25 good equal 20/400 ETDRS chart , without coexist choroidal neovascularization . Physical ability reasonable expectation maintain followup appointment . Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous ophthalmologic investigation trial Any patient proliferative diabetic retinopathy , diabetic macular edema , uveitis , history ocular trauma , severe glaucoma , neovascular agerelated macular degeneration Duration previous treatment IPT exceed two year . Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either : Require medical surgical intervention 12month study period prevent treat visual loss might result condition , If allow progress untreated , could likely contribute loss least 2 Snellen equivalent line Best Corrected Visual Acuity ( BCVA ) study period Prior/Concomitant Treatment : Previous steroid ( oral ) within 30 day precede Day 0 Previous participation study investigational drug within 30 day precede Day 0 ( exclude vitamin mineral ) Prior participation Genentech ranibizumab clinical trial within 60 day . History receive intravitreal injection ranibizumab , bevacizumab , pegaptanib , intravitreal medication within 60 day first injection . History receive intravitreal subtenons triamcinolone within 90 day first injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Idiopathic Parafoveal Telangiectasia</keyword>
	<keyword>Macular Telangiectasia</keyword>
	<keyword>Macula Lutea/pathology</keyword>
	<keyword>Retinal Diseases/pathology</keyword>
	<keyword>Retinal Pigments/metabolism</keyword>
	<keyword>Telangiectasis/metabolism</keyword>
	<keyword>Telangiectasis/pathology</keyword>
</DOC>